Drug misuse - naltrexone: review decision - November 2010 information
History
Documents created during the development process.
Background information
-
-
Drug misuse - naltrexone: appendix A - review decision paper considered by the Institute's Guidance Executive
-
-
TA115 Drug misuse - naltrexone: appendix A - provisional matrix of stakeholders
-
TA115 Drug misuse - naltrexone: appendix A - provisional matrix of stakeholders (PDF 57 KB)
-
TA115 Drug misuse - naltrexone: appendix B - proposal paper presented to the Institute's Guidance Executive
-
Drug misuse - naltrexone: Final appraisal determination
-
Drug misuse - naltrexone: Final appraisal determination information
-
Drug misuse - naltrexone: Final appraisal determination document
-
Drug misuse - naltrexone: Final appraisal determination document (PDF 81 KB)
-
Drug misuse - naltrexone: Response to consultee and commentator comments on the ACD
-
Drug misuse - naltrexone: Response to consultee and commentator comments on the ACD (PDF 47 KB)
-
Consultee and commentator comments on the appraisal consultation document
-
Drug misuse - naltrexone, consultee and commentator comments: Welsh Assembly Government
-
Drug misuse - naltrexone, consultee and commentator comments: Welsh Assembly Government (PDF 71 KB)
-
Drug misuse - naltrexone, consultee and commentator comments: Specialist Clinical Addiction Network
-
-
Drug misuse - naltrexone, consultee and commentator comments: Royal College of Psychiatrists
-
-
Drug misuse - naltrexone, consultee and commentator comments: Royal College of Nursing
-
Drug misuse - naltrexone, consultee and commentator comments: Royal College of Nursing (PDF 13 KB)
-
Drug misuse - naltrexone, consultee and commentator comments: NHS Quality Improvement Scotland
-
-
Drug misuse - naltrexone, consultee and commentator comments: Department of Health, Social Service and Public Safety (revised)
-
-
Drug misuse - naltrexone, consultee and commentator comments: Department of Health, Social Service and Public Safety
-
-
Drug misuse - naltrexone, consultee and commentator comments: British Association for Psychopharmacology
-
Drug misuse - naltrexone: Appraisal consultation document
Drug misuse - naltrexone: Evaluation report
-
Drug misuse - naltrexone: Evaluation report
-
Overview
-
-
Assessment report
-
-
Pinson
-
-
Non-manufacturer submissions
-
Royal College of Psychiatrists
-
-
Royal College of Nursing
-
-
Royal College of General Practitioners
-
-
Association of Nurses in Substance Abuse (ANSA)
-
-
Bristol-Myers Squibb Pharmaceuticals
-
-
Consultee and commentator comments on the assessment report
-
Welsh Assembly Government (WAG)
-
-
SCAN
-
-
Royal College of Psychiatrists
-
-
Royal College of Nursing
-
-
Royal College of General Practitioners
-
-
Quality Improvement Scotland (NHS)
-
-
British Association for Psychopharmacology
-
Drug misuse - naltrexone: final protocol
-
Drug misuse - naltrexone: final protocol
-
Drug misuse - naltrexone: Final scope
-
Drug misuse - naltrexone: Final scope
-
Drug misuse - naltrexone: comments on draft scope
-
Drug misuse - naltrexone: comments on draft scope
-
(Archive) Drug misuse - naltrexone: Draft scope
-
(Archive) Drug misuse - naltrexone: Draft scope
-
(Archive) Drug misuse - naltrexone: Provisional list of consultees and commentators
-
(Archive) Drug misuse - naltrexone: Provisional list of consultees and commentators
-
(Archive) Drug misuse - naltrexone: Provisional list of consultees and commentators (PDF 29 KB)